Go Pro
→ They told you not to miss this one (From Thor Metals) (Ad)tc pixel
NASDAQ:ABSI

Absci Q2 2026 Earnings Report

Absci logo
$10.28 +0.07 (+0.69%)
As of 11:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Absci EPS Results

Actual EPS
N/A
Consensus EPS
-$0.15
Beat/Miss
N/A
One Year Ago EPS
N/A

Absci Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.89 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Absci Announcement Details

Quarter
Q2 2026
Date
8/11/2026
Time
After Market Closes
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Absci Earnings Headlines

AbSci (ABSI) Receives a Buy from H.C. Wainwright
July 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ABSI-Q/pressreleases/3163945/absci-absi-receives-a-buy-from-h-c-wainwright/
BTIG Remains a Buy on AbSci (ABSI)
July 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ABSI/pressreleases/3096535/btig-remains-a-buy-on-absci-absi/
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
July 14 at 1:00 AM  |  American Alternative (Ad)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), AbSci (ABSI) and Viking Therapeutics (VKTX)
June 26, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ABSI-Q/pressreleases/13843/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-absci-absi-and-viking-therapeutics-vktx/
Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?
June 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/absci-absi-37-8-abs-080654598.html
Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD) and AbSci (ABSI)
June 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ABSI-Q/pressreleases/1718/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-and-absci-absi/
See More Absci Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Absci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Absci and other key companies, straight to your email.

About Absci

Absci (NASDAQ:ABSI) (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework. By integrating AI-driven protein design with advanced screening processes, the company seeks to rapidly advance promising biologic candidates from concept through lead optimization. Absci’s platform supports research in areas such as oncology, immunology and metabolic disease, providing partners with drug-like protein candidates and data insights that can de-risk preclinical development.

Founded in 2018 and headquartered in Seattle, Washington, Absci maintains collaborative relationships with multiple global pharmaceutical organizations and operates additional research facilities in the United States. The company’s leadership team brings together experts in protein engineering, data science and drug development, aiming to transform biologics discovery through technological innovation. As Absci continues to expand its pipeline partnerships and platform capabilities, it remains focused on delivering scalable solutions for the next generation of protein therapeutics.

View Absci Profile
Earnings Tools